Search - tctmd.com

Displaying 21 - 40 of 44

Sort: Relevancy | Date

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Todd Neale

January 21, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

Shelley Wood

October 01, 2021

News Daily News

FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction

Michael O'Riordan

August 19, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Shelley Wood

May 27, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Shelley Wood

May 06, 2020

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

Advertisement

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

FDA Approves Empagliflozin for Treatment of HFpEF

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

TCTMD’s Top 10 Most Popular Stories for September 2021

FDA Green-lights Empagliflozin for HF With Reduced Ejection Fraction

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

FDA Approves Dapagliflozin for CKD Patients

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content